New myeloma treatment regimen shows good results. PDF Print
EurekAlert: The researchers, led by Andrzej J. Jakubowiak, M.D., Ph.D., professor of medicine and director of the multiple myeloma program at the University of Chicago Medical Center, found that combining carfilzomib, a next generation proteasome inhibitor, with two standard drugs – lenalidomide and low-dose dexamethasone compared favorably to other frontline regimens.

...

 
Share |
Copyright © 2024 Global Dialysis. All Rights Reserved.